ATE373640T1 - Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren - Google Patents

Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren

Info

Publication number
ATE373640T1
ATE373640T1 AT97901158T AT97901158T ATE373640T1 AT E373640 T1 ATE373640 T1 AT E373640T1 AT 97901158 T AT97901158 T AT 97901158T AT 97901158 T AT97901158 T AT 97901158T AT E373640 T1 ATE373640 T1 AT E373640T1
Authority
AT
Austria
Prior art keywords
methylphenidate
bisaroyl
tartar
acids
optical resolution
Prior art date
Application number
AT97901158T
Other languages
German (de)
English (en)
Inventor
Michael Harris
Hooshang Zavareh
Original Assignee
Celltech Pharma Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601228.1A external-priority patent/GB9601228D0/en
Application filed by Celltech Pharma Europ Ltd filed Critical Celltech Pharma Europ Ltd
Application granted granted Critical
Publication of ATE373640T1 publication Critical patent/ATE373640T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0004Crystallisation cooling by heat exchange
    • B01D9/0013Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Thermal Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97901158T 1996-01-22 1997-01-22 Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren ATE373640T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601228.1A GB9601228D0 (en) 1996-01-22 1996-01-22 Resolution
GB9700156 1997-01-20

Publications (1)

Publication Number Publication Date
ATE373640T1 true ATE373640T1 (de) 2007-10-15

Family

ID=26308503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901158T ATE373640T1 (de) 1996-01-22 1997-01-22 Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren

Country Status (12)

Country Link
EP (1) EP0883608B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4163748B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR19990081891A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE373640T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU716570B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2242595A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ225198A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69738154T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP9900798A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9805870A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK98098A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1997027176A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
EP0879228B1 (en) * 1996-02-02 2002-10-30 Medeva Europe Limited Process for the preparation of d-threo-(r,r)-methyl phenidate and recycling of undesired enantiomers by epimerisation
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
AU2199901A (en) 1999-12-17 2001-06-25 Medeva Europe Limited The treatment of convulsive states
WO2003031411A2 (en) * 2001-10-12 2003-04-17 Sention, Inc. Direct resolution of racemic threo-methylphenidate hydrochloride
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
US7897777B2 (en) * 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
WO2010128517A1 (en) 2009-05-07 2010-11-11 Malladi Drugs & Pharmaceuticals Ltd. Improved process for the preparation of d-threo-ritalinic acid hydrochloride by resolution of dl-threo-ritalinic acid using chiral carboxylic acid
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt) 2011-03-23 2022-01-11 Ironshore Pharmaceuticals & Development, Inc Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
JPH07247286A (ja) * 1994-01-18 1995-09-26 Sankyo Co Ltd 含窒素環状化合物の光学分割方法
DE69517810T2 (de) * 1994-05-16 2000-12-14 Merrell Pharmaceuticals Inc., Cincinnati Verfahren und diastereomere salze nützlich bei der racemattrennung von racemischer 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylphenyl essigsäure sowie entsprechende diastereomere salze

Also Published As

Publication number Publication date
EP0883608A1 (en) 1998-12-16
JP2000517288A (ja) 2000-12-26
SK98098A3 (en) 1999-03-12
DE69738154D1 (de) 2007-10-31
CZ225198A3 (cs) 1998-12-16
JP4163748B2 (ja) 2008-10-08
CA2242595A1 (en) 1997-07-31
AU1450397A (en) 1997-08-20
WO1997027176A1 (en) 1997-07-31
KR19990081891A (ko) 1999-11-15
MX9805870A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1999-01-31
HUP9900798A2 (hu) 1999-07-28
AU716570B2 (en) 2000-03-02
HUP9900798A3 (en) 1999-11-29
DE69738154T2 (de) 2008-06-12
EP0883608B1 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
ATE373640T1 (de) Optische auflösung von methylphenidat mittels 0, 0'-bisaroyl-weinsäuren
ATE130604T1 (de) Neue arylethylaminderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE312072T1 (de) Substituierte cyclische verbindungen, verfahren zu ihrer herstellung sowie sie enthaltende pharmazeutische zusammensetzungen
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
PT93246A (pt) Processo para a preparacao de compostos pirrolicos substituidos e de composicoes farmaceuticas que os contem
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
ATE156818T1 (de) Polyfluoralkylthiopoly(ethylimidazolium)- verbindungen, verfahren zu ihrer herstellung und ihre verwendung als biozide mittel
DE69122866D1 (de) Herstellung von substituierten piperidinen
UA26431A (uk) Похідhі сиh-ізомеру цефалоспориhу, їх оптичhо активhі аhтиподи або рацемічhа суміш, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі
RU95106684A (ru) Би-ароматические ацетиленовые соединения с группой адамантила, фармацевтическая и косметическая композиция на их основе
DE69207429D1 (de) Verfahren zur herstellung von substituierten piperidinen
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
DE69433012D1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
FI881609A0 (fi) Dihydropyridinamider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ATE71388T1 (de) Sofort vernetzbare zusammensetzung.
ES433860A1 (es) Procedimiento de preparacion de derivados del acido ciclo- pentano-carboxilico.
ES2076616T3 (es) Derivados de aminoacidos sulfurosos opticamente activos, su preparacion, su polimerizacion en polimeros opticamente activos y su uso.
ATE199909T1 (de) Derivate der phosphonsäure, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
BG88028A (bg) Амиди на циклометилен-1,2-дикарбоксилни киселини с терапевтична активност,методи за получаването им и фармацевтични състави, които ги съдържат
DK0464488T3 (da) Optisk aktive N-alfa-fluoracryloylaminosyre-derivater, deres fremstilling, de deraf fremstillede optisk aktive polymerer og deres anvendelse til spaltning af racemater
ATE127465T1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
ES488971A1 (es) Procedimiento de preparacion de agentes de tratamiento de fibras queratinicas
DE3887102D1 (de) Substituierte Derivate von 20,21-Dinoreburnamenin, Verfahren zur Herstellung und so hergestellte Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties